Not all body fat carries the same health risk. The fat you can see and pinch — stored just beneath the skin — behaves very differently from the fat stored deep within the abdominal cavity, wrapped around the liver, pancreas, and intestines. This deeper fat, called visceral fat, is one of the most clinically significant risk factors in metabolic medicine — and it can be elevated even in people whose weight and BMI appear normal.
Visceral Fat vs Subcutaneous Fat
Body fat falls into two broad anatomical categories:
- Subcutaneous fat sits beneath the skin across the body — the fat you can grab at the abdomen, thighs, arms, and buttocks. It has some metabolic activity but is largely a passive energy store.
- Visceral fat is stored within the peritoneal cavity, surrounding and infiltrating the abdominal organs. It is metabolically active in a harmful sense — releasing inflammatory signalling molecules and fatty acids that directly affect liver and systemic metabolism.
Two people with identical body weight and BMI can have vastly different amounts of visceral fat. This is why BMI, which measures total weight relative to height, is a poor predictor of metabolic risk at the individual level.
Why Visceral Fat Is Clinically Dangerous
Visceral fat's danger lies in its location and metabolic behaviour. Unlike subcutaneous fat, visceral adipose tissue drains into the portal circulation — the blood supply that flows directly to the liver before reaching systemic circulation. This means the liver is exposed to high concentrations of free fatty acids and adipokines (signalling molecules secreted by fat cells) released from visceral depots.
The consequences include:
- Hepatic insulin resistance — impaired insulin signalling in the liver, leading to elevated blood glucose and compensatory hyperinsulinaemia
- Dyslipidaemia — elevated triglycerides and reduced HDL cholesterol
- Systemic inflammation — visceral fat secretes pro-inflammatory cytokines including IL-6, TNF-α, and resistin at higher rates than subcutaneous fat
- Non-alcoholic fatty liver disease (NAFLD) — excess free fatty acid delivery to the liver promotes hepatic fat accumulation
Study: Desprès and Lemieux (2006) published a landmark review in Nature synthesising decades of research on abdominal adiposity and its relationship to the metabolic syndrome.
Key finding: The authors proposed that visceral fat accumulation is the central pathophysiological link between abdominal obesity and cardiometabolic risk. Visceral fat releases free fatty acids directly into portal circulation, leading to hepatic insulin resistance and secondary dyslipidaemia — a cascade that drives type 2 diabetes and cardiovascular disease independently of total body fatness.
Significance: This "portal hypothesis" helps explain why waist circumference is a better predictor of metabolic risk than BMI — because waist circumference correlates more closely with visceral fat volume than total body weight does.
Study: Fox et al. (2007) used CT imaging to quantify visceral and subcutaneous adipose tissue in approximately 3,000 men and women from the Framingham Heart Study community cohort.
Design: Cross-sectional analysis examining the association between CT-measured fat compartments and cardiovascular risk factors including hypertension, dyslipidaemia, insulin resistance, and metabolic syndrome.
Key finding: Visceral fat volume was independently associated with adverse cardiometabolic risk factor profiles across the full range of BMI — including among individuals with BMI in the normal range. At any given level of BMI or total body fat, higher visceral fat was associated with significantly worse metabolic outcomes. Subcutaneous fat showed weaker and less consistent associations.
Clinical implication: Metabolic risk cannot be fully assessed from weight or BMI alone. Abdominal fat distribution — specifically visceral fat — is a critical independent risk factor.
How to Assess Visceral Fat
CT scanning is the clinical gold standard for quantifying visceral fat volume, but it involves radiation exposure and is not used for routine screening. Dual-energy X-ray absorptiometry (DEXA) can estimate visceral fat with reasonable accuracy and is increasingly available in clinical settings.
For practical assessment, waist circumference is the most accessible and clinically validated proxy. The 2009 international harmonised criteria for metabolic syndrome define elevated waist circumference as:
| Population | Men (risk threshold) | Women (risk threshold) |
|---|---|---|
| European / Caucasian | ≥ 94 cm (37 in) | ≥ 80 cm (31.5 in) |
| South Asian / Chinese / Japanese | ≥ 90 cm (35.4 in) | ≥ 80 cm (31.5 in) |
| American (NCEP ATP III) | ≥ 102 cm (40 in) | ≥ 88 cm (34.6 in) |
Waist circumference should be measured at the level of the umbilicus (navel), at the end of a normal exhale, without compressing the skin. Waist-to-height ratio (waist circumference divided by height, both in the same unit) is an alternative metric; a ratio above 0.5 is considered elevated risk across most ethnic groups.
What Visceral Fat Raises Risk For
Elevated visceral fat is independently associated with increased risk of:
- Type 2 diabetes — via hepatic and peripheral insulin resistance
- Cardiovascular disease — via dyslipidaemia, hypertension, and systemic inflammation
- Metabolic syndrome — a cluster of risk factors (central obesity, elevated triglycerides, low HDL, hypertension, elevated fasting glucose) that together substantially raise cardiovascular and diabetes risk
- Non-alcoholic fatty liver disease (NAFLD)
- Sleep apnoea — abdominal fat accumulation affects respiratory mechanics
- Certain cancers — including colorectal and postmenopausal breast cancer
What Actually Reduces Visceral Fat
Visceral fat responds well to lifestyle intervention — often more rapidly than subcutaneous fat. A systematic review by Chaston and Dixon (2008) found that both dietary and exercise-induced weight loss reduced visceral fat, and that visceral fat was typically lost in greater proportion relative to total fat mass during weight loss periods.
Calorie Deficit and Overall Weight Loss
Any intervention that produces a meaningful calorie deficit will reduce visceral fat as part of overall weight loss. Ross et al. (2000) conducted a randomised trial in obese men comparing diet-induced weight loss (no exercise) to exercise-induced weight loss (no dietary change), with both groups targeting a matched calorie deficit of approximately 700 kcal/day. Both groups lost similar total body weight — but the exercise group achieved significantly greater reductions in visceral fat despite comparable overall fat loss, indicating that aerobic exercise preferentially reduces visceral fat beyond the calorie deficit effect alone.
Aerobic Exercise — Preferential Visceral Fat Reduction
The Ross et al. finding has been replicated across multiple studies: aerobic exercise consistently produces greater visceral fat reduction than diet-alone interventions of similar calorie deficit, and can reduce visceral fat even in the absence of significant total body weight change in some individuals. The mechanism likely involves direct effects of exercise on hepatic fat metabolism and visceral adipose tissue lipolysis, independent of the calorie deficit created.
Sleep and Stress Management
Chronic sleep restriction and elevated cortisol from psychological stress are independently associated with visceral fat accumulation. Inadequate sleep alters appetite-regulating hormones and promotes calorie-dense food preference; chronic stress drives cortisol-mediated preferential fat deposition in the visceral compartment. Addressing both supports visceral fat reduction beyond the direct effects of diet and exercise.
What Does Not Work: Spot Reduction
No exercise targets visceral fat removal from a specific anatomical location. Abdominal exercises build abdominal muscles but do not selectively mobilise visceral fat. Fat loss is systemic — where it comes from first depends on genetics, hormones, and individual biology, not where you exercise.
Visceral fat is a clinical risk factor, not simply a cosmetic concern. In health assessments, waist circumference is increasingly measured alongside BMI and blood pressure because it captures metabolic risk that weight alone misses. A person with a "normal" BMI but a waist circumference above the population-specific threshold carries meaningful elevated risk for metabolic syndrome and cardiovascular disease.
If you have elevated waist circumference alongside other risk factors — high blood pressure, elevated fasting glucose, or abnormal lipid levels — these should be evaluated by a healthcare professional. Lifestyle intervention can meaningfully reduce visceral fat and associated risk, but the timeline and appropriate targets depend on individual clinical context.
- Desprès JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–887.
- Fox CS et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39–48.
- Alberti KG et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
- Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes. 2008;32(4):619–628.
- Ross R et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men: a randomized, controlled trial. Ann Intern Med. 2000;133(2):92–103.